10-K/A: Silexion Therapeutics Files 10-K/A Amendment for FY 2025

Silexion Therapeutics Corp files an amendment to its 2025 annual report to correct internal control reporting dates.

Summary

• This filing is an amendment (Amendment No. 1) to Silexion Therapeutics Corp's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• The amendment is solely to correct typographical errors in Part II, Item 9A. Controls and Procedures.
• Specifically, the date for management's evaluation of internal control over financial reporting was incorrectly stated as December 31, 2024, and has been corrected to December 31, 2025.
• The company confirms that there have been no material changes to its internal control over financial reporting during the three-month period ended December 31, 2025.
• The filing includes updated versions of Exhibits 3.5 and 10.5.2, reflecting shareholder-approved matters since the original filing.
• Certifications from the CEO and CFO regarding the accuracy of the report and the effectiveness of disclosure controls and internal financial reporting are included.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a procedural amendment to correct a date and does not introduce new financial or operational information.

Positives

• Management and the certifying officers have affirmed that the financial statements and information presented in the report are materially accurate and not misleading.
• Disclosure controls and procedures were evaluated and found to be effective as of December 31, 2025.
• Internal control over financial reporting was evaluated and management concluded it was effective as of December 31, 2025.
• No material changes affecting internal control over financial reporting occurred during the fourth fiscal quarter of 2025.

Future Outlook

This amendment does not contain new forward-looking statements or guidance; it solely addresses corrections to previously filed information regarding internal controls.

Management Comments

• "Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report."
• "Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report."
• Management concluded that disclosure controls and procedures were effective as of December 31, 2025.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Industry Context

StockSavvy.ai notes that this filing is a procedural amendment to correct a date related to internal controls, which is common in SEC filings. It does not provide new operational or financial performance data for Silexion Therapeutics Corp.

Corporate Governance

Stakeholder Impact

• Shareholders: The correction of a date in the internal controls section is unlikely to have a direct impact on shareholders, as it does not change the company's financial performance or operational status.
• Management and Employees: The filing reaffirms the effectiveness of internal controls, which is a standard requirement and does not indicate new issues or changes in responsibilities.
• Auditors and Audit Committee: The amendment clarifies the reporting date for internal control evaluations, ensuring accurate record-keeping for these bodies.

Next Steps

• The company will continue to maintain and evaluate its disclosure controls and procedures and internal control over financial reporting.
• The company will file future reports in compliance with SEC regulations.

Key Dates

Keywords

10-K/A, Amendment, Silexion Therapeutics Corp, Internal Control, Financial Reporting, Disclosure Controls, SEC Filing, Annual Report, Sarbanes-Oxley Act